Poseida Therapeutics Inc PSTX

NAS: PSTX | ISIN: US73730P1084   9/05/2024
2,710 USD (0,00%)
(0,00%)   9/05/2024

9 mei 2024 · Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting · Persbericht

2 mei 2024 · Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology · Persbericht

1 mei 2024 · Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology · Persbericht

18 april 2024 · Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting · Persbericht

17 april 2024 · Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus · Persbericht

8 april 2024 · Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma · Persbericht

1 april 2024 · Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

25 maart 2024 · Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer · Persbericht

19 maart 2024 · Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference · Persbericht

13 maart 2024 · Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma · Persbericht

7 maart 2024 · Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 · Persbericht

4 maart 2024 · Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

4 januari 2024 · Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones · Persbericht

10 december 2023 · Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting · Persbericht

9 november 2023 · Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023 · Persbericht

7 november 2023 · Poseida Therapeutics to Present at Two Upcoming Investor Conferences · Persbericht

2 november 2023 · Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition · Persbericht

9 oktober 2023 · Poseida Therapeutics Announces Leadership Transition · Persbericht

5 september 2023 · Poseida Therapeutics to Present at Two Upcoming Investor Conferences · Persbericht

8 augustus 2023 · Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023 · Persbericht

Mijn selecties